argenx ARGX.BR · EUR
Health Care · Biotechnology · Euronext Brussels · 🇧🇪 Belgium
Euro Stoxx 50
853.80
+4.66%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About argenx
Its shares trade on Euronext Brussels under the ticker ARGX.BR. It has been listed since 10 July 2014. It is a member of the Euro Stoxx 50. In the fiscal year to 31 December 2025, it reported revenue of $3.60bn and net income of $1.12bn. At that date it held total assets of $7.52bn and shareholders' equity of $6.35bn.
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. The company is headquartered in Breda, Noord-Brabant. The company went IPO on 2014-07-10. The company creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 10 Jul 2014
- Employees
- 188
Leadership
Pay as last reported
- Mr. Peter VerhaegheNon-Executive Independent Chairman of the Board$592,234
- Mr. Tim van HauwermeirenChief Executive Officer, Co-Founder, Executive Director, since 2008$7.8m
- Mr. Anthony RosenbergNon-Executive Independent Vice Chairman of the Board$557,234
- Mr. Karl GubitzChief Financial Officer$5.3m
- Ms. Karen MasseyChief Operating Officer$6.2m
- Mr. Peter UlrichtsChief Scientific Officer
- Mr. Arjen LemmenVice President - Corporate Development and Strategy
- Ms. Malini MoorthyGeneral Counsel
- Dr. Luc TruyenChief Medical Officer
- Mrs. Andria WilkGlobal Head of Quality
- Dr. Ana CespedesNon-Executive Independent Director$544,734
- Mr. James DalyNon-Executive Independent Director$567,234
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 78
- Environment
- 86
- Social
- 99
- Governance
- 49
- Direct emissions (scope 1)
- 378 t
- Energy emissions (scope 2)
- 183 t
- Value chain emissions (scope 3)
- 432,786 t
- Women in the workforce
- 57.665%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- argenx SE possesses several strengths that contribute to its success:
Weaknesses
- Despite its strengths, argenx SE also faces certain weaknesses:
Opportunities
- argenx SE can capitalize on the following opportunities:
Threats
- argenx SE faces the following potential threats:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.